Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: Results from a 20-year surveillance study
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
PURPOSE: Known risk factors for the development of colorectal dysplasia or cancer in ulcerative colitis are total colonic involvement and long duration of the disease. It has recently been suggested that presence of primary sclerosing cholangitis is another independent risk factor-especially for proximal colorectal dysplasia or cancer-and that treatment with sulfasalazine might reduce the frequency of colorectal cancer in ulcerative colitis; the present study was undertaken to shed light on the validity of these theories. METHODS: A total of 143 patients with ulcerative colitis underwent regular colonoscopies and multiple biopsies in a 20-year surveillance program for studies of long-standing total ulcerative colitis. Fifty-one of the patients developed colorectal dysplasia or cancer. Patient records were scrutinized retrospectively for information of presence of primary sclerosing cholangitis, site of the colorectal malignancy, and results of sulfasalazine treatment. RESULTS: Nineteen of the patients had primary sclerosing cholangitis; these ran a significantly higher risk of developing colorectal dysplasia or cancer than patients with ulcerative colitis only. All colorectal cancers (n = 3) and 75 percent of all colorectal dysplasias or cancers among patients with primary sclerosing cholangitis were located in the proximal part of the colon, whereas 36 percent were found in that same region among the patients with ulcerative colitis without primary sclerosing cholangitis (P = 0.02). Sulfasalazine treatment showed no significant protective effect on the development of colorectal dysplasia or cancer in patients with ulcerative colitis. CONCLUSION: The risk evaluation, as assessed by multivariate analysis, shows that primary sclerosing cholangitis proves to be an additional and independent risk factor for the development of colorectal dysplasia or cancer in patients with ulcerative colitis-particularly in the proximal part of the colon. The findings do not support the theory that sulfasalazine treatment exerts a protective effect against colorectal dysplasia or cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lundqvist, K., & Broomé, U. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02258391 · Cited by 159
Self-citationUnconjugated secondary bile acids in the serum of patients with colorectal adenomas.
Bayerdörffer, E., Mannes, G. A., Ochsenkühn, T., Dirschedl, P., Wiebecke, B., & Paumgartner, G. (1995) · Gut · doi:10.1136/gut.36.2.268 · Cited by 146 · cited 3×
“02 Age at onset of UC* 27 (24-29) 25 (18-31) 0.”
Cited by
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
Rutter, M., Saunders, B., Wilkinson, K., Rumbles, S., Schofield, G., Kamm, M., Williams, C., Price, A., Talbot, I., & Forbes, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.010 · Cited by 1,255
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
Loftus, E. V., Harewood, G. C., Loftus, C. G., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., Jewell, D. A., & Sandborn, W. J. (2005) · Gut · doi:10.1136/gut.2004.046615 · Cited by 777
Primary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. H. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 592
Velayos, F. S., Terdiman, J. P., & Walsh, J. M. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41442.x · Cited by 548
Farraye, F. A., Odze, R. D., Eaden, J., & Itzkowitz, S. H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.035 · Cited by 494
Van Assche, G., Dignass, A., Bokemeyer, B., Danese, S., Gionchetti, P., Moser, G., Beaugerie, L., Gomollón, F., Häuser, W., Herrlinger, K., et al. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.005 · Cited by 463
Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies
Lakatos, P. L., & Lakatos, L. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3937 · Cited by 442
Diagnosis and management of dysplasia in patients with inflammatory bowel diseases
Itzkowitz, S. H., & Harpaz, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.025 · Cited by 423
van Staa, T. P., Card, T., Logan, R. F., & Leufkens, H. G. M. (2005) · Gut · doi:10.1136/gut.2005.070896 · Cited by 287
Systematic review with meta‐analysis: the declining risk of colorectal cancer in ulcerative colitis
Castaño‐Milla, C., Chaparro, M., & Gisbert, J. P. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12651 · Cited by 268
Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis
Vries, A. B. D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i6.1956 · Cited by 253
Jrgensen, K. K., Grzyb, K., Lundin, K. E. A., Clausen, O. P. F., Aamodt, G., Schrumpf, E., Vatn, M. H., & Boberg, K. M. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21699 · Cited by 149
Jørgensen, K. K., Lindström, L., Cvancarova, M., Castedal, M., Friman, S., Schrumpf, E., Foss, A., Isoniemi, H., Nordin, A., Holte, K., et al. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.685754 · Cited by 65
Metadata
- Authors
- Lindberg, B. U., Broomé, U., & Persson, B.
- Venue
- Diseases of the Colon & Rectum
- Published
- 2001-01
- Volume
- 44
- Issue
- 1
- Pages
- 77-83
- ISSN
- 0012-3706 (ISSN-L)
- OpenAlex
- W1973441719
- Cited by
- 121
- References
- 2
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.